Atovaquone maintenance therapy prevents reactivation of toxoplasmic encephalitis in a murine model of reactivated toxoplasmosis. - Wikidata - awgldk - TriplyDB

Atovaquone maintenance therapy prevents reactivation of toxoplasmic encephalitis in a murine model of reactivated toxoplasmosis.

Atovaquone maintenance therapy prevents reactivation of toxoplasmic encephalitis in a murine model of reactivated toxoplasmosis.

http://www.wikidata.org/entity/Q37625142

about

Persistence of Toxoplasma gondii in the central nervous system: a fine-tuned balance between the parasite, the brain and the immune system Nucleotide-oligomerization-domain-2 affects commensal gut microbiota composition and intracerebral immunopathology in acute Toxoplasma gondii induced murine ileitis Great efficacy of sulfachloropyrazine-sodium against acute murine toxoplasmosis Forward genetic screening identifies a small molecule that blocks Toxoplasma gondii growth by inhibiting both host- and parasite-encoded kinases Uptake of apolipoprotein E fragment coupled liposomes by cultured brain microvessel endothelial cells and intact brain capillaries.In vitro and in vivo activities of 1-hydroxy-2-alkyl-4(1H)quinolone derivatives against Toxoplasma gondii.The impact of Toll-like-receptor-9 on intestinal microbiota composition and extra-intestinal sequelae in experimental Toxoplasma gondii induced ileitis.The IFN-γ-inducible GTPase, Irga6, protects mice against Toxoplasma gondii but not against Plasmodium berghei and some other intracellular pathogens.Maternal and congenital toxoplasmosis, currently available and novel therapies in horizon Atovaquone ameliorate gastrointestinal toxoplasmosis complications in a pregnancy model Artemisone and artemiside control acute and reactivated toxoplasmosis in a murine model Antiparasitic treatment suppresses production and avidity of Toxoplasma gondii-specific antibodies in a murine model of acute infection*.Dectin-1-CD37 association regulates IL-6 expression during Toxoplasma gondii infection.Nanomedicine advances in toxoplasmosis: diagnostic, treatment, and vaccine applications.Significant reduction of brain cysts caused by Toxoplasma gondii after treatment with spiramycin coadministered with metronidazole in a mouse model of chronic toxoplasmosis.Comparison of dynamic expressions of Tim-3 and PD-1 in the brains between toxoplasmic encephalitis-resistant BALB/c and -susceptible C57BL/6 mice.SDS-coated atovaquone nanosuspensions show improved therapeutic efficacy against experimental acquired and reactivated toxoplasmosis by improving passage of gastrointestinal and blood-brain barriers.The role of apolipoprotein E in uptake of atovaquone into the brain in murine acute and reactivated toxoplasmosis.Inhibition of Calcium Dependent Protein Kinase 1 (CDPK1) by Pyrazolopyrimidine Analogs Decreases Establishment and Reoccurrence of Central Nervous System Disease by Toxoplasma gondii.Fetomaternal and Pediatric Toxoplasmosis.Formulation and characterization of atovaquone nanosuspension for improved oral delivery in the treatment of malaria.Upregulated expression of Tim-3 involved in the process of toxoplasmic encephalitis in mouse model.A Repurposed Drug for Brain Cancer: Enhanced Atovaquone Amorphous Solid Dispersion by Combining a Spontaneously Emulsifying Component with a Polymer Carrier.Evaluation of Current and Emerging Antimalarial Medicines for Inhibition of Toxoplasma gondii Growth in Vitro

P2860

Q27026477-1334DD34-917E-4C8C-8BC2-F264B4E4E09B Q27314835-FF824DAD-FEC0-4F28-AC28-2CB24B561D78 Q28396159-BC744FB5-0749-43C5-9837-F9D227183566 Q28539663-5B78E8AA-6BBF-4F4F-8E3D-18130E77BC26 Q33495327-B3396547-605D-4353-91CC-F6ECDF703404 Q33558897-A1BB324B-3236-4855-A5DB-C0573B8A3C4F Q33756071-CF4ABC91-D001-4A33-8EA4-8C59D1555EB4 Q33940781-E2DB2E97-AFF0-49D4-85D1-EA72FF23C0AB Q33943894-86144B65-FF33-4799-B062-44A7DB38B9FE Q36577126-832ACBBF-07EB-41C6-9A69-4F2DA191799F Q37392848-18B80DE8-27BA-4F6D-A513-492507EB85F6 Q37531268-B4419B23-D6C6-4CF5-9D4F-05A99A1C3D5C Q38990827-6456CD16-F6A6-416F-9534-AC8A65D2CF32 Q39287046-35991AE6-630B-4F90-8246-F68DD29D7D20 Q41968777-60C2C6FD-8096-4EFC-A0B7-0974C7C21611 Q42239888-75CAF446-0DC3-451D-9188-32105D651CF7 Q44164523-E64BC7B6-E948-4731-B451-B38477265329 Q46102626-7620A021-F1DB-45A6-A6A2-5E41F2B784BF Q46159933-C8F0269C-8B9D-468A-A32F-EBF92C3DB002 Q47565444-4B84726E-726F-453A-A77A-457EDEB6E2CC Q47833185-C7F0B0F2-2E0F-4B9C-8ED4-3D8DF766B6D9 Q51063368-38D1C013-ABD9-4582-B365-09069B5C74FA Q55687695-7DF251D7-E30E-49B5-A3A7-931C9C3034F8 Q56344152-924F17F2-D209-4B65-98AA-55904662EF4A

P2860

Atovaquone maintenance therapy prevents reactivation of toxoplasmic encephalitis in a murine model of reactivated toxoplasmosis.

http://www.wikidata.org/entity/Q37625142

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on December 2004

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Atovaquone maintenance therapy ...... of reactivated toxoplasmosis.

@en

Atovaquone maintenance therapy ...... of reactivated toxoplasmosis.

@nl

type

label

Atovaquone maintenance therapy ...... of reactivated toxoplasmosis.

@en

Atovaquone maintenance therapy ...... of reactivated toxoplasmosis.

@nl

prefLabel

Atovaquone maintenance therapy ...... of reactivated toxoplasmosis.

@en

Atovaquone maintenance therapy ...... of reactivated toxoplasmosis.

@nl

P1433

Q37625142-D030E1DF-D2B0-4178-866B-08C69D1CE32B

P1476

Q37625142-6E3BF332-D670-4C59-B230-E95A134907F5

P2093

Q37625142-377D4B51-5192-460B-8F87-158FD4AAF41E

Q37625142-623E9ADD-6B09-41BA-9736-3941B04CCCFC

Q37625142-7407FF8F-BA66-43CB-BF03-EAF5811B3E40

Q37625142-878067E9-28EE-419F-8392-8523BBCF6302

Q37625142-880D250B-0CE9-4DDF-A098-69CAB24F0FC7

Q37625142-897DFA6C-F622-44CB-B535-8111BC1B31C9

Q37625142-A9C40B8A-6332-4002-A420-87EEB4AE1DF1

Q37625142-B1E61CF0-E231-4F7A-AC6B-88B6EE635605

Q37625142-C807F266-8D11-4115-BF21-1D00783016C3

Q37625142-E1F35B3F-76C1-4D9B-9477-4CB276445DE6

P2860

Q37625142-003EE749-E598-458E-98E6-1A8B8A347C95

Q37625142-070AA609-1584-4BB9-A82B-4E4D95FC167E

Q37625142-3517FC39-3306-4514-B809-8380BC6E3126

Q37625142-37B3DB08-5464-4626-98F6-E5FDF9D28022

Q37625142-3D7E170F-E9ED-418B-A917-B96DFC42236F

Q37625142-3F9ACA75-A27C-41A9-954B-BF513C9E6EDB

Q37625142-45B80F83-4C62-41F2-BF36-204098D86105

Q37625142-465977DA-900A-41E8-A618-23FB8DD52CF0

Q37625142-530189DE-DE0B-4423-ADCF-838DC58838D0

Q37625142-952AD0EF-B3F4-4335-99E7-079CAA0C5706

P304

Q37625142-9A6FE056-9FAC-46E8-BDC4-38F99FB8A624

P31

Q37625142-25732574-D3A6-45FC-A7A0-E1351D22A272

P356

Q37625142-5A7152AF-DC00-4AFB-B610-ACF4CCD02A60

P407

Q37625142-D1D4797F-10E3-41B9-80B2-DB7E828B534F

P433

Q37625142-1A334EA3-75AF-4E09-AA42-4CE135314A60

P478

Q37625142-6523C7FA-1EAA-43DB-A505-4EF8AA3EB67E

P50

Q37625142-3ED1B77A-2E02-4D15-BDF0-6177B02B6F42

P577

Q37625142-FD69AF45-C121-4146-B81E-8736C022E0AB

P698

Q37625142-632843EA-7B11-4C4C-9903-2CF9B71A7031

P921

Q37625142-0C23DA71-5071-4E56-A503-66F879A4A494

P932

Q37625142-50B0F9EE-0E6E-4450-957D-619B16757159

P356

AAC.48.12.4848-4854.2004

P1433

Antimicrobial Agents and Chemotherapy

P1476

Atovaquone maintenance therapy ...... of reactivated toxoplasmosis.

@en

P2093

Faris Nadiem Bushrab

http://www.w3.org/2001/XMLSchema#string

Hartmut Stocker

http://www.w3.org/2001/XMLSchema#string

Ildiko R Dunay

http://www.w3.org/2001/XMLSchema#string

Keikawus Arasteh

http://www.w3.org/2001/XMLSchema#string

Klaus Borner

http://www.w3.org/2001/XMLSchema#string

Markus M Heimesaat

http://www.w3.org/2001/XMLSchema#string

Michael Kurowski

http://www.w3.org/2001/XMLSchema#string

Oliver Liesenfeld

http://www.w3.org/2001/XMLSchema#string

Rainer H Müller

http://www.w3.org/2001/XMLSchema#string

Rudolf Fitzner

http://www.w3.org/2001/XMLSchema#string

P2860

Immunodeficiency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene

Sources of toxoplasma infection in pregnant women: European multicentre case-control study. European Research Network on Congenital Toxoplasmosis

Efficacy of atovaquone combined with clindamycin against murine infection with a cystogenic (Me49) strain of Toxoplasma gondii

Remarkable in vitro and in vivo activities of the hydroxynaphthoquinone 566C80 against tachyzoites and tissue cysts of Toxoplasma gondii

Synergistic effect of clindamycin and atovaquone in acute murine toxoplasmosis

Atovaquone nanosuspensions show excellent therapeutic effect in a new murine model of reactivated toxoplasmosis

Drug evaluation of concurrent Pneumocystis carinii, Toxoplasma gondii, and Mycobacterium avium complex infections in a rat model

Antiparasitic agent atovaquone

Toxoplasmic encephalitis in AIDS.

P304

4848-4854

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.48.12.4848-4854.2004

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

48

http://www.w3.org/2001/XMLSchema#string

P50

Oliver Liesenfeld

P577

2004-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15561866

http://www.w3.org/2001/XMLSchema#string

P921

P932

529229

http://www.w3.org/2001/XMLSchema#string